TSE:MFC

Manulife Financial (MFC.TO)

57.04
+0.49 (0.87%)
as of Jun 25, 2026, 8:00:00 pm Market Open.
1634 watching
0
Investor Insights
star iconJun 25, 2026, 12:00 am

This summary was created by AI, based on 28 opinions in the last 12 months.

Manulife Financial (MFC) has garnered mixed opinions from market experts. Many analysts recognize MFC's potential, particularly highlighting its growth in Asia and successful capital generation from legacy businesses. The consensus seems to indicate a solid long-term investment due to its steady dividend yield, with several experts suggesting that patience may be required as the stock navigates short-term fluctuations. Despite some concerns about past performance and market positioning against competitors, the company's strategy and management is viewed positively. Analysts mention the current valuation as reasonable compared to peers, suggesting MFC is a better option for income rather than growth. Overall, there is a cautious optimism about MFC's capabilities and future direction.

consensus icon
Consensus
Hold
valuation icon
Valuation
Fair Value
review icon
Similar
SLF-T
HOLD
Last quarter was disappointing. Great expansion into Asia. Recent drop in yields has hurt all the financials. Dividend yield, growth, safety. Not everything in your portfolio fires at the same time. Some things you just tuck away and wait. Good company, growing. Yield is 4-5%, better than cash or bonds.
PAST TOP PICK
(A Top Pick Jul 17/20, Up 34%) There is no reason to sell it. The shares remain cheap and offer an excellent yield. They offer good upside potential.
HOLD
Massive investment in Asia is one of the positives. Long-term opportunity is good. Interest rate sensitivity of the lifecos can have a magnified effect the stock price. As a long-term investor, don't worry about this.
TOP PICK
Goes back to the caution on broader market. Has not seen a big run like other stocks. Yields over 4% at current levels and could increase it. Continued growth trends. Collect your dividend while you are in a stable entity and wait for upside. Good for when things look frothy. (Analysts’ price target is $29.02)
PAST TOP PICK
(A Top Pick Jun 05/20, Up 31%) They have had a great run. The company has underlying good things happening. Looking for better days.
HOLD

Likes it and a lot of the insurers. A good long-term name, though he owns SLF and GWO instead. Expects dividend to increase over time by 8-10% yearly. Pullback due to interest rates coming down. Rates will probably move higher 12-24 months out. Asia exposure is a growing segment. Yield is 4%.

HOLD
It is the most discounted insurance company in Canada. It is trading at this level because it has been the performance laggard for quite some time. It has become a show-me story. However if you were going to buy an insurance company, this would be the one to buy. There is the chance of a bounce back or a trading opportunity. It has a decent dividend while you wait for an uptick.
BUY ON WEAKNESS
Would hold and it is getting close to adding back to it. They are one of the biggest at risk plays of interest rates going down. They are geared to benefit from higher interest rates. Moves out of financials is hurting their stock price. Would add on weakness.
TOP PICK
Canada's largest lifeco. Geographically diversified. Asia is demographically advantaged. The US business is lagging, but they're working on this. Canadian business is steady-eddy. Investing relentlessly in tech. Stock is inexpensive. Yield is 4.44%. (Analysts’ price target is $28.83)
BUY
The most volatile of Canadian lifecos, because it has the greatest difference between reported earnings and core earnings due to having a ton of both market and interest rate exposure. Likes it. Nice franchise in the US and Asian exposure to the emerging consumer. It's done increasingly well the last 10 years.
BUY

Interesting, likes the name. Perhaps management doesn't pay out more to shareholders or buy back shares because they want to expand or keep cash on hand. Doing well. Will benefit long-term from growth in Asia. 7-8x forward earnings, with 7-9% earnings growth going forward. Revenues and earnings will grow. He owns SLF and GWO instead. Yield of 4.5%.

BUY

Banks or lifecos? She likes both sectors, so it's not an either-or question. Banks will benefit from the reopening/recovery. She expects earnings upside and revisions probably later this year. Bank stocks have had a nice rally this year, but long term they remain attractive given their yields. The lifecos' valuations remain good, and wealth management offers key growth. She likes MFC's presence in Asia for its strong long-term growth. She owns TD, Royal and BNS.

DON'T BUY
He does not own life insurance companies as they are the most commoditized form of insurance. The banks have done better than the insurance companies (11% vs. 5%) unless you are looking for a short term trade, he would favour a bank. (Analysts’ price target is $29.00)
BUY

MFC vs. SLF Equally good. Prefers MFC for the great Asian franchise, which has a lot of opportunity. Has also built a great asset management business that has continued to do well. MFC has a great growth profile at a cheaper multiple. MFC gets the nod, but you can own both. They're great businesses that will continue to pay a good dividend for many years.

BUY

He continues to try to look at the big picture. It is cheaper than SLF-T with potentially more horsepower in terms of growth and it has a higher dividend yield. The opportunity in MFC-T comes from management. Changes they make do not come overnight. The recent drop is a buying opportunity.

Showing 241 to 255 of 2,281 entries